Wockhardt Limited (NSE:WOCKPHARMA)
1,796.20
-59.30 (-3.20%)
Oct 23, 2026, 11:50 AM IST
Wockhardt Earnings Call Transcripts
Fiscal Year 2026
-
The group has transformed into an innovation-led healthcare company, achieving strong financial growth and launching Zaynich, a novel antibiotic with global potential. Zaynich targets resistant infections, with a robust U.S. and India launch strategy, and aims for $1.5–$2 billion peak annual sales.